Winship's Associate Director for Cancer Outcomes Research, Deborah Bruner, PhD, RN, is the principal investigator of a three-year study that reveals a popular erectile dysfunction drug is not effective for prostate cancer patients undergoing radiation therapy.
Findings showed that tadalafil (Cialis) was not associated with improved overall sexual function or satisfaction in the more then 200 men studied.
"The good news is that only 20 to 25 percent of the study group experienced erectile dysfunction," explains Bruner. "This is lower than we expected but still a large number of people in this population who receive radiotherapy prostate cancer treatment. Our findings are significant because they warrant the need to find alternative strategies and dosing to prevent this very common condition."
The study was conducted by the Radiation Therapy Oncology Group's Community Clinical Oncology Program.